PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
Clinicopathologic and Molecular Characterization of Low-Grade, Early-Stage, and HER2-Positive Invasive Breast Carcinoma
Publication: American Journal of Clinical Pathology, 2025, Vol. 163, No. 6Authors: Natasha Hunter, MD; Lisa Han, MD; Haley Corbin, MD; Eric Q. Konnick, MD, MS, ; William R. Gwin III, MD; Shaveta Vinayak, MD; Hannah Linden, MD; William Audeh, MD; Lavanya Samraj, MD, MS; Andrea R. Menicucci, PhD; FLEX Investigators Read More
Real-World Evidence From FLEX: Utility of MammaPrint in Guiding Treatment Planning for Patients Aged 70 and Older With Early-Stage Breast Cancer
Publication: ASCO® 2025 Authors: Reshma Mahtani, Ana Sandoval-Leon, Anna Schrieber, Cathy Graham, Lauren Carcas, Naomi Dempsey, Victoria Poillucci, Michelle Landon, Christa Dreezen, William Audeh Title: Real-world Evidence from FLEX: Utility of MammaPrint in guiding treatment planning for patients aged 70 and older with early-stage breast cancer Background: Older women Read More
Association of MammaPrint and Clinical Outcomes by Race Among 5000 Individuals With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX
Publication: ASCO® 2025 Authors: Erin Cobain, Priyanka Sharma, Kent Hoskins, Michael Berry, Gregory Vidal, Jamie Alberty, Nicole Gordon, Harshini Ramaswamy, Nicole Stivers, Andrea Menicucci, William Audeh, Joyce O’Shaughnessy Title: Association of MammaPrint and clinical outcomes by race among 5000 individuals with HR+HER2- early stage breast cancer enrolled in FLEX Read More
Molecular Insights Into HR+/HER2+ Early-Stage Breast Cancer: Neoadjuvant Therapy Responses by MammaPrint and BluePrint Genomic Subtypes
Publication: ASCO® 2025 Authors: Laila Samiian, Adam Brufsky, Sahra Uygun, Isha Kapoor, Victoria Poillucci, Joyce O’Shaughnessy, William Audeh Title:Molecular Insights into HR+/HER2+Early-Stage Breast Cancer: Neoadjuvant Therapy Responses by MammaPrint and BluePrint genomic subtypes Background: Clinical HER2+ (cHER2+) early breast cancer (EBC) represents 15-20% of invasive EBC and is typically Read More
Association of ImPrintTN Signature With Survival Outcomes by Race in Basal-Type Triple Negative Breast Cancer
Publication: ASCO® 2025 Authors: Priyanka Sharma, Shane R. Stecklein, Denise M. Wolf, Christina Yau, Laura Esserman, Laura van t Veer, David B. Page, Harshini Ramaswamy, Sahra Uygun, Josien Haan, Nicole Stivers, Andrea Menicucci, William Audeh, Joyce O'Shaughnessy Title: Association of ImPrintTN signature with survival outcomes by race in Basal-Type Read More
The impact of the 80-gene signature on pCR and chemotherapy treatment decisions in early-stage breast cancer: A FLEX analysis
Publication: ESMO Breast Cancer 2025 Authors: Brufsky, et al. Title: The impact of the 80-gene signature on pCR and chemotherapy treatment decisions in early-stage breast cancer: A FLEX analysis Background: The BluePrint (BP), 80-gene signature, provides insight into the intrinsic subtype of early-stage breast cancer (EBC). This study evaluates Read More
Real World Evidence of MammaPrint® and BluePrint® utility for informing axillary surgery decisions in the neoadjuvant setting
Publication: ASBRS 2025 Authors: Thompson et al. Title: Real World Evidence of MammaPrint® and BluePrint® utility for informing axillary surgery decisions in the neoadjuvant setting Introduction: Decisions regarding the extent of axillary surgery in HR+HER2- early-stage breast cancer (EBC) are primarily based on clinical factors, including age, T-stage, and Read More
